Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy

Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy

Abstract Background Cancer immunotherapy is a relatively new approach to cancer treatment. Peptides that target specific pathways and cells involved in immunomodulation can potentially improve the efficacy of cancer therapy. Recently, we reported iPD-L1 as a novel inhibitor peptide that specifically...

Full description

Saved in:
Bibliographic Details
Main Authors: Myrna Luna-Gutiérrez, Erika Azorín-Vega, Rigoberto Oros-Pantoja, Blanca Ocampo-García, Pedro Cruz-Nova, Nallely Jiménez-Mancilla, Gerardo Bravo-Villegas, Clara Santos-Cuevas, Laura Meléndez-Alafort, Guillermina Ferro-Flores
Format: Article
Language:English
Published: SpringerOpen 2025-01-01
Series:EJNMMI Radiopharmacy and Chemistry
Subjects:
PD-1
177Lu-labeled iPD-L1
Immunotherapy
177Lu targeted radiation therapy
Online Access:https://doi.org/10.1186/s41181-025-00328-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s41181-025-00328-9

Similar Items